Core Viewpoint - Toxin Pharmaceutical (301089) announced the establishment of a wholly-owned subsidiary, Toxin Pharmaceutical (Inner Mongolia) Co., Ltd., to leverage local energy advantages for optimizing cost structure and enhancing overall development strategy [1] Group 1: Company Strategy - The subsidiary will be registered in Hohhot, Inner Mongolia, with a registered capital of 50 million yuan, focusing on the research, production, and sales of fermentation-related products [1] - The company has a mature microbial fermentation technology platform and extensive experience in traditional mutagenesis and molecular breeding, which supports its operational capabilities [1] Group 2: Market and Economic Context - Inner Mongolia is recognized as a key energy supply base in China, with abundant wind, solar, and thermal power resources, providing significant energy endowment advantages [1] - The low electricity prices in Inner Mongolia are expected to effectively reduce energy costs, which are critical to the company's core competitiveness due to the high energy consumption characteristics of the fermentation process [1]
拓新药业：内蒙古设立全资子公司 推动公司整体发展战略落地